01 June 2006
An assessment of downward trends in neurodevelopmental disorders in the United States following removal of thimerosal from childhood vaccines.David A. Geier, Mark R. Geier
Med Sci Monit 2006; 12(6): CR231-239 :: ID: 451248
Background: The US is in the midst of an epidemic of neurodevelopmentaldisorders (NDs). Thimerosal is an ethylmercury-containing compound added to some childhood vaccines.Several previous epidemiological studies conducted in the US have associated Thimerosal-containing vaccine(TCV) administration with NDs. Material/Methods: An ecological study was undertaken to evaluate NDs reportedto the Vaccine Adverse Event Reporting System (VAERS) from 1991 through 2004 by date of receipt and bydate of vaccine administration. The NDs examined included autism, mental retardation, and speech disorders.Statistical trend analysis was employed to evaluate the effects of removal of Thimerosal on the proportionof NDs reported to VAERS. Results: There was a peak in the proportion of ND reports received by VAERSin 2001-2002 and in the proportion of ND reports by date of vaccine administration in 1998. There weresignificant reductions in the proportion of NDs reported to VAERS as Thimerosal was begun to be removedfrom childhood vaccines in the US from mid-1999 onwards. Conclusions: The present study provides thefirst epidemiological evidence showing that as Thimerosal was removed from childhood vaccines, the numberof NDs has decreased in the US. The analysis techniques utilized attempted to minimize chance or bias/confounding.Additional research should be conducted to further evaluate the relationship between TCVs and NDs. Thisis especially true because the handling of vaccine safety data from the National Immunization Programof the CDC has been called into question by the Institute of Medicine of the National Academy of Sciencesin 2005.
Keywords: Child, Preschool, Child Development Disorders, Pervasive - epidemiology, Preservatives, Pharmaceutical - toxicity, Thimerosal - toxicity, United States, Vaccines - adverse effects
01 November 2023 : EditorialEditorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is Declared
Med Sci Monit 2023; 29:e942960
29 Nov 2023 : Laboratory ResearchCTRP13 Mitigates Endothelial Cell Ferroptosis via the AMPK/KLF4 Pathway: Implications for Atherosclerosis P...
Med Sci Monit In Press; DOI: 10.12659/MSM.942733
28 Nov 2023 : Clinical ResearchImpact of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography on Therapeutic Decisions and ...
Med Sci Monit In Press; DOI: 10.12659/MSM.942122
28 Nov 2023 : Clinical ResearchLong-Term Outcomes of Decompression and Grafting in Acute Pathological Proximal Femur Fractures in Children...
Med Sci Monit In Press; DOI: 10.12659/MSM.943031
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
14 Dec 2022 : Clinical ResearchPrevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels
Med Sci Monit 2022; 28:e937990
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292